News & Updates

COVID-19 shots for tots OK’d

01 Jul 2022 by

The 2-year wait is over.

COVID-19 shots for tots OK’d

01 Jul 2022

High-dose antidepressants up risk of out-of-hospital cardiac arrest

01 Jul 2022 by

Patients on high-dose citalopram (>20 mg) and high-dose escitalopram (>10 mg) are more likely to experience out-of-hospital cardiac arrest (OHCA) than those on sertraline, while users of high-dose mirtazapine (>30 mg) have a higher OHCA rate than those on duloxetine, a study has shown.

High-dose antidepressants up risk of out-of-hospital cardiac arrest

01 Jul 2022

$Do bDMARDs prevent osteoporotic fractures in RA patients?$

Do bDMARDs prevent osteoporotic fractures in RA patients?

01 Jul 2022

Use of biological disease-modifying antirheumatic drugs (bDMARDs) appears to have no benefit in the prevention of osteoporotic fractures among patients with rheumatoid arthritis (RA), according to the results of a recent study.

Do bDMARDs prevent osteoporotic fractures in RA patients?

01 Jul 2022

Ultra-high-dose methylcobalamin may reduce clinical progression in early-stage ALS

01 Jul 2022 by

Ultra-high-dose methylcobalamin (MeCbl) slowed functional decline in individuals with early-stage amyotrophic lateral sclerosis (ALS) with moderate progression, the JETALS* study has shown.

Ultra-high-dose methylcobalamin may reduce clinical progression in early-stage ALS

01 Jul 2022

Androgen receptor expression tied to poor urothelial carcinoma outcomes

01 Jul 2022 by

In patients with metastatic urothelial carcinoma (mUC), a positive expression of androgen receptor (AR) appears to worsen survival outcomes, according to a recent study.

Androgen receptor expression tied to poor urothelial carcinoma outcomes

01 Jul 2022

Doxycycline plus zinc helps shield against COVID-19

01 Jul 2022

In healthcare workers, prophylactic therapy with doxycycline plus zinc seems to reduce the risk of contracting SARS-CoV-2 infection, according to a study.

Doxycycline plus zinc helps shield against COVID-19

01 Jul 2022

Novel PPARγ modulator shows therapeutic potential in acne vulgaris

01 Jul 2022

In the treatment of patients with acne vulgaris, the investigational peroxisome proliferator-activated receptor-γ (PPARγ) modulator N-acetyl-GED-0507-34-LEVO (NAC-GED) 5% gel appears to help clear lesions and improve acne severity while being safe, according to the results of a phase IIb study.

Novel PPARγ modulator shows therapeutic potential in acne vulgaris

01 Jul 2022

Decitabine as good as, but safer than, chemo in AML

01 Jul 2022 by

Extended treatment with decitabine is as good as, but safer than, standard induction chemotherapy (IC) in older patients with acute myeloid leukaemia (AML), according to a phase III study presented at EHA 2022.